Sm04554

[Hubris]

Interesting article http://www.readcube.com/articles/10.1038%2Fnbt0216-120

But can't read the second page. If someone has access to it please copy it here

Very interesting article. What I could read of it anyway.

[stratowich]

Interesting article http://www.readcube.com/articles/10.1038%2Fnbt0216-120

But can't read the second page. If someone has access to it please copy it here

Nice to see a well written article on AGA in a high profile journal like Nature Biotechnology.

There isn't actually too much information on the second page (the article only consists of 2 pages). However, there is mentioning of another Milan-based company developing a topical DHT antagonist which sounds to have potentials:
"The oral DHT inhibitor Propecia, also used in a higher dose for treating enlarged prostates, slows hair loss but has potential side effects that include impotence and dizziness. Moreover, the drug is approved only for men, since exposures during pregnancy can harm the fetus.
Instead, Cassiopea of Milan, Italy is developing a topical DHT antagonist called Breezula for alopecia treatment. According to the company’s chief executive officer, Diana Harbort, the drug breaks down into harmless byproducts on entering circulation. If approved, Breezula would be the first anti-DHT compound available for use in both men and women. Currently a boutique firm specializing in dermatology, Cassiopeia was spun off by its parent company, Cosmo Pharmaceuticals, in January 2015."

[allTheGoodNamesAreTaken]

"“We have good evidence that bimatoprost [Latisse] stimulates hair growth, but skin absorption with our formulation was less than 1% so most of it was wasted,” he says. Allergan has since developed a new formulation with increased scalp penetrance, which will enter phase 1 safety testing in February."

I didn't know about this.

[baldybald]

We need to pay to see it though

[TooMuchHairWontKillYou]

Interesting article http://www.readcube.com/articles/10.1038%2Fnbt0216-120

But can't read the second page. If someone has access to it please copy it here

[20legend]

On clinical trails, the SM phase 2b trials isn't recruitment any more. Guess they got the required people.
It say it should finish by April so hopefully sometime next month we got a positive update from them.

In the meantime all we can do if find out about their molecule. Coz I think many ppl will be willing to give this a try.

[Hemo]

I'm not gonna harp on about the phase IIb delay anymore, but I just re-read their initial study's timeline which "involved a 90‐day once‐a‐day treatment period and a 45‐day post‐treatment follow up." (this was taken from their website). Extending their phase IIb by 45 days simply allows them to take the same 45 day post-treatment measure as the initial phase II, at least in my opinion (for a total 135 day trial, same as the first).

[paleocapa89]

What is interesting, is that if I am interpreting this correctly they only started enrollment of patients to their Phase II clinical trail of their OA drug in 2015 November 6. And they are already hiring a sales director?

https://www.samumed.com/files/begins-enrollment-in-a-phase-ii-clinical-trial-for-the-treatment-of-osteoarthritis-oa-11-06-2015.PDF

[rdawg]

The first bullet specifies "Set strategic priorities from a market access standpoint pertaining to Samumed’s initial launch of a novel OA drug" - OA meaning Osteoarthritis. I'd be pretty excited if it said AA but it seems this person wouldn't be focused on that, at least not yet.

If they do launch this hairloss drug, it wont be for another couple years, doubtful they'd hire someone for that right now, it's too premature.

[TooMuchHairWontKillYou]

The first bullet specifies "Set strategic priorities from a market access standpoint pertaining to Samumed’s initial launch of a novel OA drug" - OA meaning Osteoarthritis. I'd be pretty excited if it said AA but it seems this person wouldn't be focused on that, at least not yet.

Oh Shi t :|

[Hemo]

Saw it today. Posted 2/1/2016

http://www.biospace.com/jobs/job-listing/director-market-access-353809

It says that Samumed is looking for director for sales "RESPONSIBILITIES: Develop market access strategy for initial drug launch and build associated team"

Maybe it's nothing special but still better than nothing :d

The first bullet specifies "Set strategic priorities from a market access standpoint pertaining to Samumed’s initial launch of a novel OA drug" - OA meaning Osteoarthritis. I'd be pretty excited if it said AA but it seems this person wouldn't be focused on that, at least not yet.

[Tomtom21]

Nice find... If you read the position it placed emphasis on the molecule for OA. Hopefully that doesnt mean they are going to prioritize the launch of that molecule before sm04554 because that molecule is just recruiting for phase 2 study now. Well just gave to wait and see what the coming months bring us.

[TooMuchHairWontKillYou]

Saw it today. Posted 2/1/2016

http://www.biospace.com/jobs/job-listing/director-market-access-353809

It says that Samumed is looking for director for sales "RESPONSIBILITIES: Develop market access strategy for initial drug launch and build associated team"

Maybe it's nothing special but still better than nothing :d

[Tomtom21]

I sent the coordinator an email, and she said the speakers are George Cotsarelis and Desmond Tobin. Unfortunately Samumed will not be there


Comb through the last link I posted... They will be presenting an electronic poster session on March 5, from 12:15-12:20 or some thing like that on their phase 1 study.... Just gotta be patient and wait for phase II results to be published

[iaskdumbquestions]

Hi
I would like to post something interested :
the meeting of north american hair research society will take place on
Friday, March 4, 2016 • 12:00 p.m. - 2:00 p.m.
Washington DC, USA
Registration is required. $25 for Members; $50 for Non-Members

Perhaps, we will have some informations about the phase 2 of SM.
And the last but not least this : the last phase 2 of SM will finish on March 2016 "A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing"

source:

https://clinicaltrials.gov/ct2/show/results/NCT02503137?term=Samumed&rank=3

http://nahrs.org/MeetingsCalendar.aspx

I sent the coordinator an email, and she said the speakers are George Cotsarelis and Desmond Tobin. Unfortunately Samumed will not be there